Drugs / ASA404
ASA404
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT01278758 | Mar → Nov 2010 | metastatic malignant neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01290380 | Feb → Nov 2010 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01278849 | Jan → Nov 2010 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01240642 | Jan → Dec 2010 | cancer of unknown primary site | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01031212 | Jan 2010 → Jun 2012 | neoplasm | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1 | NCT01299415 | Aug 2009 → Sep 2010 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01285453 | Mar → Dec 2009 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01299701 | Dec 2008 → Jul 2009 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00674102 | Apr 2008 → Mar 2009 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00863733 | May 1996 → Mar 2000 | cancer | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00003697 | Oct 1995 → Dec 1998 | cancer of unknown primary site | University of Glasgow | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00832494 | Sep 2004 → Aug 2007 | non-small cell lung carcinoma | Antisoma Research | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01071928 | Jun 2010 | urothelial carcinoma | Hoosier Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 2 | NCT01057342 | Jan 2010 → May 2011 | lung cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00111618 | May 2005 → Jun 2007 | prostate cancer | Antisoma Research | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00738387 | Dec 2008 → Dec 2010 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00662597 | Apr 2008 → May 2010 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASA404 | “This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.” NCT00832494 ↗ |
| Known as | 5,6-dimethylxantheone-4-acetic acid | “ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA” NCT01290380 ↗ |
| Known as | AS1404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00111618 ↗ |
| Known as | DMXAA | “ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA” NCT01290380 ↗ |
| Known as | DXAA | “ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA” NCT01290380 ↗1“ASA404, DMXAA or DXAA” NCT01278758 ↗ |
| Known as | vadimezan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01057342 ↗ |
| Action | Inhibit | “In vitro studies showed nonspecific phosphodiesterase inhibition by DMXAA.” PMID 19387077 ↗ Apr 2009 |
| Modality | Small molecule | “ASA404 (5,6-dimethylxanthenone-4-acetic acid) is a small-molecule, flavonoid tumor-vascular disrupting agent.” PMID 22263047 ↗ Dec 2010 |
| Route | Intravenous | “ASA404 is administered intravenously every 21 days” NCT00674102 ↗ |